Is Neu­ro­crine primed for takeover? Rev­enue soars on In­grez­za sales

Kevin Gor­man, CEO of Neu­ro­crine Bio­sciences, presents at a Jef­feries in­vestor con­fer­ence in 2013. Bloomberg/via Get­ty Im­ages

Boom­ing sales of new­ly ap­proved drug In­grez­za is dri­ving Neu­ro­crine Bio­sciences’ $NBIX stock steadi­ly north. The un­ex­pect­ed ear­ly suc­cess of the drug might bump Neu­ro­crine’s sta­tus as a wor­thy takeover tar­get.

The San Diego com­pa­ny’s share price closed at $72.78, up 20% com­pared to mar­ket close Wednes­day. All the fuss is over In­grez­za’s im­pres­sive sales for Q3. Each quar­ter the com­pa­ny has out­paced an­a­lysts’ ex­pec­ta­tions, and Q3 was no ex­cep­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.